Multiple Myeloma Information Center
Each year in the United States, close to 20,000 people are diagnosed with multiple myeloma. Thanks to improvements in treatment, however, multiple myeloma patients are living longer. It is estimated that there are more than 56,000 multiple myeloma survivors in the U.S. today.
Advances in targeted therapy, chemotherapy, and stem cell transplantation have contributed to improved multiple myeloma survival. In addition, advances in supportive care have made multiple myeloma treatment more tolerable, leading to improved quality of life.
Understanding multiple myeloma treatment options, the role of different doctors specializing in the treatment of multiple myeloma, and how and when to access new and innovative multiple myeloma treatment options available through clinical trials is essential in order to achieve the best outcome from multiple myeloma treatment.
The Cancer Consultants Multiple Myeloma Information Center has been designed to help patients understand multiple myeloma and multiple myeloma treatment options while providing ongoing information, inspiration, support, and community to individuals affected by a diagnosis of multiple myeloma.
Headline Multiple Myeloma News 
Treatment of Relapsed Myeloma with Second Stem Cell Transplant Appears Safe
Study explores toxicity and response rates.
Velcade Improves Survival with Multiple Myeloma
Final results from Phase III VISTA trial
CancerConnect Live Web Chat with Dr. Barrie Cassileth from Memorial Sloan-Kettering Cancer Center on Complementary Cancer Therapies on Thursday, November 17th at 6PM EST
Live Web Chat with Barrie R. Cassileth, PhD, Chief, Integrative Medicine Service;...
Multiple Myeloma Tips
Know the Signs of Depression in Cancer Patients Because a significant number of cancer patients—an estimated 25 percent—experience...
Understanding Stem Cell Transplants High-dose chemotherapy and bone marrow or blood stem cell transplantation (SCT) remains the best treatment available for selected patients with certain types of leukemia.
Chemotherapy-induced Nausea and Vomiting (CINV): No Longer an Inevitable Side Effect of Chemotherapy for Multiple Myeloma Management may be effective and convenient. It’s no surprise that cancer patients...
Multiple Myeloma Management
Inspiration, Hope & Resources
Jack & Jill Late Stage Cancer Foundation Jon Albert, founder of the Jack & Jill Late Stage Cancer Foundation shows the...
Moving Bodies, Changing Lives Moving On Aerobics helps women regain joy of movement and physical fitness after...
Where Kids Can Be Kids… And Cancer Takes a Back Seat Cancer camps for kids provide fun and camaraderie for children facing down a cancer...
Multiple Myeloma Clinical Trials
06-108 – Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma (MM) Who Are Not Considered Candidates for High-Dose Chemotherapy (HDT) and Autologous Stem Cell Transplantation (SCT): VELCADE (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VD) versus VELCADE, Melphalan, and Prednisone (VMP) (C05009)
C05009 – Randomized, Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myelome Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE? (Bortezomib) for Injection, Thalidomide, and Dexamethasone (VTD) versus VELCADE? (Bortezomib) and Dexamethasone (VD) versus VELCADE? (Bortezomib), Melphalan and Prednisone (VMP)
MM03 – PHASE II TRIAL OF ARSENIC TRIOXIDE AND THALIDOMIDE IN THE TREATMENT OF PATIENTS WITH REFRACTORY MULTIPLE MYELOMA
 |
 |
 |
 |
